- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.07. | Ondine Biomedical - Keynote Address at 8th Annual Photodynamic Day | - | RNS | ||
| 30.06. | Ondine Biomedical - Result of AGM and voting results | - | RNS | ||
| 30.06. | Ondine Biomedical - Leeds drops SSI 78% over Mupirocin with Steriwave | - | RNS | ||
| 22.06. | Ondine Biomedical highlights progress on Lantern phase 3 study | 3 | Alliance News | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 22.06. | Ondine Biomedical - Update on US Phase 3 Pivotal Study | - | RNS | ||
| 18.06. | Ondine Biomedical - Leeds Drops SSIs by 78.5% in Complex Brain Surgery | - | RNS | ||
| 08.06. | Ondine Biomedical grants stock options, RSUs and warrants | 1 | Investing.com | ||
| 08.06. | Ondine Biomedical - Grant of Options and RSUs, and Issue of Warrants | - | RNS | ||
| 04.06. | Ondine Biomedical: Strategiewechsel führt zu Umsatzwachstum und hohem Verlust | 3 | Investing.com Deutsch | ||
| 04.06. | Increased investment sees Ondine Biomedical post widened annual loss | 1 | Alliance News | ||
| 04.06. | Ondine Biomedical setzt jährliche Hauptversammlung für 30. Juni an | 1 | Investing.com Deutsch | ||
| 04.06. | Ondine Biomedical schedules annual meeting for June 30 | 1 | Investing.com | ||
| 04.06. | Ondine Biomedical - Notice of AGM | - | RNS | ||
| 04.06. | Ondine Biomedical - 2025 Full Year Results and Annual Report | - | RNS | ||
| 28.05. | Ondine Biomedical - Notice of Results and Investor Presentation | - | RNS | ||
| 26.05. | Ondine Biomedical - Steriwave ICU Study Outcomes Presented at CSRT2026 | - | RNS | ||
| 06.05. | hInsight-NX reduces stake in Ondine Biomedical to 7.53% | 2 | Investing.com | ||
| 06.05. | Ondine Biomedical - Notification of major holdings - hInsight-NX, LLC | - | RNS | ||
| 06.05. | Ondine Biomedical - Notification of major holdings - Carolyn Cross | - | RNS | ||
| 05.05. | Ondine Biomedical - Notification of major holdings - Pentwater | - | RNS |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,670 | +10,62 % | Dividendenbekanntmachungen (07.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABC ARBITRAGE SA FR0004040608 - 0,04 EUR ACCIONA SA ES0125220311 - 5,7486 EUR AMICA SA PLAMICA00010 2,5 PLN 0,5829 EUR ANY BIZTONSAGI... ► Artikel lesen | |
| VIRAX BIOLABS GROUP | 9,250 | +190,88 % | Morning Market Movers: Virax Biolabs, Aimei Health Technology, Sadot Group, Ionis Pharmaceuticals See Big Swings | BEIJING (dpa-AFX) - At 8:35 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| COGENT BIOSCIENCES | 40,790 | +2,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 133,39 | +0,11 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 62,00 | -8,46 % | Tarsus buys iRenix Medical for $75M, gains late-stage eye care asset IRX-101 | ||
| ABSCI | 11,280 | +1,62 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BEAM THERAPEUTICS | 36,040 | -2,28 % | BofA bestätigt Kaufempfehlung für Beam Therapeutics nach Schiedsspruch | ||
| VERA THERAPEUTICS | 42,180 | -0,59 % | Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner | BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Officer... ► Artikel lesen | |
| ERASCA | 19,570 | +3,71 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 47,070 | +1,66 % | Oppenheimer initiates Edgewise Therapeutics stock with outperform rating | ||
| RECURSION PHARMACEUTICALS | 3,795 | +2,02 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,610 | +0,39 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| ALUMIS | 30,200 | +1,55 % | Alumis Aktie erreicht Rekordhoch bei 30,67 USD | ||
| CG ONCOLOGY | 73,21 | +4,89 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| RELAY THERAPEUTICS | 20,200 | +2,90 % | JPMorgan stuft Relay Therapeutics zum Start mit "Overweight" ein |
Das Unternehmen ONDINE BIOMEDICAL INC CDIS kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,150 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONDINE BIOMEDICAL INC CDIS finden Sie auf Wallstreet Online.